Alosetron Hydrochloride5-HT3 receptor antagonist,potent and highly selective CAS# 122852-69-1 |
- Dihydroberberine
Catalog No.:BCN2573
CAS No.:483-15-8
- Pectolinarigenin
Catalog No.:BCN5813
CAS No.:520-12-7
- Carnosol
Catalog No.:BCN1055
CAS No.:5957-80-2
- Hypaconine
Catalog No.:BCN8640
CAS No.:63238-68-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 122852-69-1 | SDF | Download SDF |
| PubChem ID | 60758 | Appearance | Powder |
| Formula | C17H19ClN4O | M.Wt | 330.81 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | 132414-02-9 | ||
| Solubility | H2O : 50 mg/mL (151.14 mM; Need ultrasonic) | ||
| Chemical Name | 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one;hydrochloride | ||
| SMILES | [H+].[Cl-].Cn1c2CCN(Cc3nc[nH]c3C)C(=O)c2c4ccccc14 | ||
| Standard InChIKey | FNYQZOVOVDSGJH-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C17H18N4O.ClH/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2;/h3-6,10H,7-9H2,1-2H3,(H,18,19);1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Alosetron Hydrochloride Dilution Calculator
Alosetron Hydrochloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.0229 mL | 15.1144 mL | 30.2288 mL | 60.4577 mL | 75.5721 mL |
| 5 mM | 0.6046 mL | 3.0229 mL | 6.0458 mL | 12.0915 mL | 15.1144 mL |
| 10 mM | 0.3023 mL | 1.5114 mL | 3.0229 mL | 6.0458 mL | 7.5572 mL |
| 50 mM | 0.0605 mL | 0.3023 mL | 0.6046 mL | 1.2092 mL | 1.5114 mL |
| 100 mM | 0.0302 mL | 0.1511 mL | 0.3023 mL | 0.6046 mL | 0.7557 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Alosetron is s Serotonin 5HT3-receptor antagonist that is used in treatment of irritable bowel syndrome.
- Alosetron (Z)-2-butenedioate
Catalog No.:BCC1343
CAS No.:122852-43-1
- Alosetron
Catalog No.:BCC1342
CAS No.:122852-42-0
- Cefoselis Sulfate
Catalog No.:BCC4769
CAS No.:122841-12-7
- Cefoselis
Catalog No.:BCC4092
CAS No.:122841-10-5
- H-D-Phe(4-F)-OH .HCl
Catalog No.:BCC3217
CAS No.:122839-52-5
- MRS 2957 triethylammonium salt
Catalog No.:BCC6133
CAS No.:1228271-30-4
- 8-Geranyloxy-5,7-dimethoxycoumarin
Catalog No.:BCN6117
CAS No.:1228175-65-2
- Sabutoclax
Catalog No.:BCC2236
CAS No.:1228108-65-3
- Marinopyrrole A
Catalog No.:BCC4098
CAS No.:1227962-62-0
- Gadodiamide
Catalog No.:BCC4663
CAS No.:122795-43-1
- GSK2334470
Catalog No.:BCC4982
CAS No.:1227911-45-6
- ACTH (1-39)
Catalog No.:BCC6028
CAS No.:12279-41-3
- Panaxyne
Catalog No.:BCN6462
CAS No.:122855-49-6
- GS-9620
Catalog No.:BCC1602
CAS No.:1228585-88-3
- TAK-632
Catalog No.:BCC3639
CAS No.:1228591-30-7
- AM966
Catalog No.:BCC1355
CAS No.:1228690-19-4
- AM-095 free base
Catalog No.:BCC1352
CAS No.:1228690-36-5
- 2-Desoxy-4-epi-pulchellin
Catalog No.:BCN6118
CAS No.:122872-03-1
- Mps1-IN-2
Catalog No.:BCC4153
CAS No.:1228817-38-6
- Ziprasidone HCl
Catalog No.:BCC2511
CAS No.:122883-93-6
- MLN0905
Catalog No.:BCC3961
CAS No.:1228960-69-7
- 12-Demethylneocaesalpin F
Catalog No.:BCN6410
CAS No.:1228964-10-0
- Tatarinoid A
Catalog No.:BCN6119
CAS No.:1229005-35-9
- GSK 9027
Catalog No.:BCC6115
CAS No.:1229096-88-1
Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome.[Pubmed:21180598]
Therap Adv Gastroenterol. 2010 May;3(3):165-72.
Irritable bowel syndrome (IBS) is a highly prevalent functional gastrointestinal disorder that causes a range of symptoms. Currently, Alosetron Hydrochloride (Lotronex(R)), a selective serotonin type 3 receptor antagonist, is the only medication approved for the treatment of severe diarrhea-predominant irritable bowel syndrome (IBS-D) in women who have inadequately responded to conventional therapy. Alosetron has demonstrated efficacy compared with placebo in clinical trials and has been shown to improve overall health-related quality of life (HRQoL). However, rare instances of ischemic colitis and severe complications of constipation have been reported. As a result, in 2000 alosetron was voluntarily withdrawn from the market but was reintroduced in 2002 with a more restricted indication and a requirement that clinicians and patients follow a prescribing program. Although the efficacy and benefit of alosetron has been clearly demonstrated, it has been used sparingly since its reintroduction. This brief review describes the history of alosetron, efficacy of alosetron in the treatment of IBS, the impact of severe IBS on HRQoL, safety considerations, the risk evaluation and mitigation strategy program under which alosetron is now prescribed, and an update on postmarketing surveillance data.
Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.[Pubmed:12809837]
Am J Gastroenterol. 2003 May;98(5):1117-22.
OBJECTIVE: Alosetron Hydrochloride (Lotronex), a potent selective 5-hydroxytryptamine(3) receptor antagonist, was approved in February, 2000 in the United States for the treatment of diarrhea-predominant irritable bowel syndrome (IBS) in women. Marketing was suspended in November, 2000, after reports of colonic ischemia and serious complications of constipation. We sought to compare the incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery among alosetron users and a cohort of patients with IBS who did not use alosetron. METHODS: We sought outcomes of colonic ischemia, hospitalized complications of constipation, and bowel surgery in 3,631 Lotronex users and 2,480 comparison IBS subjects using diagnoses, procedures, and drugs recorded in the UnitedHealthcare insurance claims database, and validated these by chart review. The initial assessment was to last for 3 yr beginning with the start of alosetron treatment and was to include 10,000 Lotronex users; however, the observation period ended by December 31, 2000, after suspension of marketing. RESULTS: There were 3631 alosetron users among members of UnitedHealthcare from March through December, 2000, and we identified 2480 comparison IBS-only patients; follow-up time averaged about 5 months in both groups. There were no instances of colonic ischemia in either cohort. Thirty instances of bowel surgery occurred, giving rates of 10.2/1000 person-yr in the alosetron cohort and 11.8/1000 person-yr in the IBS/no alosetron cohort. There were three cases of hospitalized complications of constipation. The incidence rates were essentially the same in alosetron users (1.24/1000 person-yr) and in IBS patients with no alosetron use (0.92/1000 person-yr). CONCLUSIONS: Alosetron users did not differ from IBS patients not using alosetron in the incidence of bowel surgery or hospitalized complications of constipation; there were no cases of colonic ischemia. The statistical upper limit of colonic ischemia rates in alosetron users was 2.28/1000 person-yr. Because of the market withdrawal, the size of the cohort and the duration of follow-up were smaller than originally planned; consequently, the statements about the safety of alosetron were necessarily limited. On June 7, 2002, the Food and Drug Administration approved alosetron for reintroduction in the U.S. market for women with severe diarrhea-related IBS.
